Study of MOv18 IgE for ovarian, endometrial, and breast cancers with a specific marker
Part of Cancer, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new antibody treatment called MOv18 IgE for patients with advanced ovarian, endometrial, or triple-negative breast cancers that have a protein called folate receptor alpha (FRα) on their tumor cells. The goal is to see if the treatment is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman aged 18 or older.
- You have advanced ovarian, endometrial, or triple-negative breast cancer that has come back or spread.
- Your tumor must have a specific marker (folate receptor alpha) on at least 5% of cells, confirmed by a test.
- You must be willing to provide a tumor sample (either from a past surgery or a new biopsy) for testing.
- You need to have a negative basophil activation test (BAT) before starting treatment.
- You must be able to do daily activities with little help (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (PF-08634404) combined with chemotherapy for women with advanced or recurrent endometrial cancer that is MMR-proficient. The goal is to see if this combination works better than standard care.
This trial tests a tailored approach to preserve fertility in women with early-stage endometrial cancer, using medications like hormones and immunotherapy based on the tumor's molecular subtype. It aims to avoid hysterectomy and keep the uterus intact.
This Phase 2 study tests mirvetuximab (a targeted antibody drug) in women whose endometrial cancer is positive for folate receptor-alpha. It aims to shrink tumors and improve outcomes, especially in cancer that has returned or kept growing after previous treatment.
This trial tests a drug called mirvetuximab soravtansine for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer that has high levels of a protein called folate receptor-alpha (FRα). It is given through a vein (IV) and aims to stop cancer from growing.
This trial tests a combination of two standard chemotherapy drugs, cyclophosphamide and bevacizumab, with or without an immunotherapy drug called envafolimab. It aims to see if adding envafolimab helps shrink tumors better in people whose cancer has come back after platinum-based chemotherapy.
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
Hear when a new Advanced Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.